ACUTAAS CHEMICALS LIMITED Fair Value
ACUTAAS · Healthcare · Current price ₹3,173.8
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹577 | 24% ROE fading to 12% over ~20 yrs, on ₹202 book |
| Relative P/E | ₹1,702 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹445 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹2,854 | Street consensus 12-month target price |
Is ACUTAAS CHEMICALS LIMITED undervalued?
DocStoX estimates the fair value of ACUTAAS CHEMICALS LIMITED at ₹1,228 per share, versus the current market price of ₹3,174. That puts the stock about -61.3% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹577), Relative P/E (₹1,702), Graham floor (₹445), Analyst target (₹2,854). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹445 (bear) to ₹1,228 (base) to ₹2,854 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ACUTAAS CHEMICALS LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.